FreeTrials & Tribulations The importance of staging lung cancer consistently and correctly worldwide April 06, 2018Vol.44 No.14By Fred R. Hirsch
Trials & Tribulations Rare Cancers, Common Need March 16, 2018Vol.44 No.11By Sandip Patel, Young Kwang Chae and Razelle Kurzrock
Conversation with The Cancer LetterFree BMS’s Farajallah: Opdivo is the only PD-1 inhibitor approved for four-week dosing March 09, 2018Vol.44 No.10By Matthew Bin Han Ong
FreeTrials & Tribulations A phase III trial seeks to determine whether diet and exercise can cure breast cancer March 02, 2018Vol.44 No.09By Jennifer A. Ligibel
FreeTrials & Tribulations Diversity within Diversity: Lessons from the Latinos of South Texas February 23, 2018Vol.44 No.08By Amelie G. Ramirez and Ruben A. Mesa
FreeTrials & Tribulations A Cancer Patient’s War on Cancer February 16, 2018Vol.44 No.07By C. Anthony "Tony" Blau
Trials & Tribulations Re: Drug Pricing My unsolicited advice to HHS Secretary Alex Azar February 02, 2018Vol.44 No.05By Patricia J. Goldsmith
FreeTrials & Tribulations Hybrid cancer centers exploring links with NCI-designated institutions January 26, 2018Vol.44 No.04By Derek Raghavan, Nicholas J. Petrelli and Donald L. "Skip" Trump
FreeTrials & Tribulations How disease-specific clinical trial finders can address gaps in study participation January 12, 2018Vol.44 No.02By David F. Arons
FreeTrials & Tribulations Cabozantinib in first-line treatment of metastatic renal cell carcinoma January 05, 2018Vol.44 No.01By Tian Zhang, Michael J. Morris, Darren R. Feldman, Toni K. Choueiri and Daniel J. George
